•  
  •  
  •  
  •  

2025-10-01 07:48:35

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores

Keywords Selected:  JBChemicalsandPharmaceuticals

Stock Report

  • Torrent Pharma to acquire controlling stake in J. B. Chemicals & Pharmaceuticals from KKR
  • J.B. Chemicals & Pharmaceuticals Ltd receives USFDA approval for ANDA Amitriptyline Hydrochloride Tablets
  • J B Chemicals and Pharmaceuticals Ltd receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
  • J B Chemicals and Pharmaceuticals Ltd reports consolidated Q4FY25 PAT of Rs. 145.69 crores
  • J.B. Chemicals & Pharmaceuticals Ltd receives ANDA approval from USFDA for Bisoprolol Tablets USP
  • J B Chemicals & Pharmaceuticals Ltd successfully completes USFDA inspection at API facility
  • USFDA inspection of J B CHemicals and Pharmaceuticals Ltd's manufacturing facility - T20 at Panoli, Gujarat
  • JB Chemicals and Pharmaceuticals Ltd Q2 FY2025 consolidated net profit at Rs. 174.57 crores
  • JB Pharma records revenue growth of 12% to INR 1004 crores in Q1 FY25
  • J B Chemicals & Pharmaceuticals Ltd updates on ANDA Approval by US FDA
  • JB Chemicals and Pharmaceuticals Ltd Q1 FY24 consolidated net profit climbs to Rs. 142.32 crores
  • USFDA inspection of J B Chemicals and Pharmaceuticals Ltd's manufacturing facility - T20 at Panoli, Gujarat
  • JB Chemicals and Pharmaceuticals Ltd consolidated Q4FY23 net profit at Rs. 87.63 crores
  • J B Chemicals and Pharmaceuticals Ltd approves interim dividend of Rs. 8.50
  • J B Chemicals and Pharmaceuticals Ltd consolidated Q3 FY2023 net profit slips QoQ to Rs. 106.10 crores
  • JB Pharma to acquire the entire Razel franchise from Glenmark Pharmaceuticals Ltd
  • Glenmark Pharmaceuticals Ltd to divest its Cardiac brand, RazelĀ®, in India and Nepal
  • J B Chemicals & Pharmaceuticals Ltd to acquire portfolio of brands
  • JB Chemicals & Pharmaceuticals Ltd receives ANDA approval for Venlafaxine Hydrochloride Extended-Release Tablets from USFDA
  • JB Chemicals and Pharmaceuticals Ltd Q1 FY2023 consolidated PAT climbs QoQ to Rs. 105.03 crores
  • JB Chemicals and Pharmaceuticals Ltd Q4 FY2022 consolidated PAT up QoQ at Rs. 84.84 crores
  • Azmarda brand for India to be assigned to J B Chemicals and Pharmaceuticals Ltd
  • JB Chemicals and Pharmaceuticals Q3 FY2021-22 consolidated net profit falls to Rs. 83.88 crores
  • J B Chemicals & Pharmaceuticals to acquire brands from Sanzyme for India market

Latest Post

  • Reliance Infrastructure Ltd clarifies on media reports related to ED survey under FEMA
  • Sri Lotus Developers & Realty Ltd launches two new projects
  • Tamilnad Mercantile Bank join Hands with Wegofin for Payment Aggregator Business
  • Waaree Energies Ltd commences Commercial Production of 950 MW Solar Module Line Manufacturing facility
  • Bizotic Commercial Ltd receives orders worth Rs. 72.25 crores


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024